IMF Videos Search Content For Healthcare Professional (76) Healthcare Provider (75) Care Partner (65) Patient (65) Series - Any - ASCO/EHA (31) ASH (30) Ask Dr. Durie (16) Community Workshops (3) Emerging Therapies (12) Facebook Live (6) Health Equity (4) IMWG (3) Living Well with Myeloma (3) Myeloma in a Minute (2) Myeloma Made Simple (6) Myeloma University (9) Q&A (6) Recent News and Developments (2) Treatments (1) Trending Searches in Myeloma (1) Topics Clinical Trials (184) Financial Considerations (15) Frontline Therapy (81) Health Equity (33) Inspirational Stories (23) Insurance (6) Lab & Imaging Tests (68) Lifestyle (47) Mental & Emotional Health (28) Myeloma 101 (54) Myeloma in the News (7) Public Policy & Advocacy (17) Q&A's (41) Recorded Seminars & Workshops (14) Recorded Webinars (23) Relapse/Refractory Myeloma (135) Research Updates (192) Symptom Management (113) Myeloma Stage Early Relapse (1–3 Lines of Therapy) (88) High-Risk Myeloma (38) High-risk Smoldering Myeloma (17) Late Relapse (4–6 Lines of Therapy) (101) MGUS (5) Newly Diagnosed (Pre-Treatment or First Treatment) (24) Smoldering Myeloma (13) Types of Therapy Immunomodulatory drugs (IMiDs) (31) Immunotherapies (CAR T; BiTE, etc.) (97) Monoclonal antibodies (33) Proteasome inhibitors (23) Stem cell transplant (24) Steroids (20) Supportive Care (36) Year Published 2026 (18) 2025 (22) 2024 (35) 2023 (39) 2022 (4) 2021 (4) 2020 (3) 2019 (2) 2018 (1) 2017 (1) 2016 (4) 2015 (2) Trusted Voices Dr. Joseph Mikhael (35) Dr. Brian GM Durie (15) Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO (5) Donna Catamero, ANP-BC, OCN, CCRC (3) Dr. María-Victoria Mateos (2) Dr. Saad Usmani (2) Dr. Sagar Lonial (1) Dr. Tom Martin (1) Sort Newest firstOldest firstA -> ZZ -> ARelevance Kilimanjaro Study: Etentamig Plus Pomalidomide-Dexamethasone Shows Robust Efficacy in Relapsed Myeloma January 21, 2026 ASH CARTITUDE-4: Exceptional Long-Term Outcomes with Cilta-cel in Standard-Risk Relapsed Myeloma January 20, 2026 ASH Anitocabtagene Autoleucel iMMagine-1 Trial: Exceptional Safety and Durability in Relapsed Myeloma January 16, 2026 ASH Understanding ELREXFIO & Bispecific Antibodies for Multiple Myeloma January 16, 2026 Emerging Therapies MajesTEC-3: Teclistamab-Daratumumab Establishes New Standard of Care in Early Relapsed Myeloma January 12, 2026 ASH Top Myeloma Research Presented at ASH 2025: Easy-to-Understand Insights for Patients and Care Partners January 7, 2026 ASH Cilta-cel Safety Enhancement: Modifiable Risk Factors for Delayed Neurotoxicity and Non-Relapse Mortality December 19, 2025 ASH IMWG Conference Series: Making Sense of Treatment December 17, 2025 IMWG IMF Virtual Myeloma Community Workshop (MCW): “What’s the ‘Right’ Answer? – Controversies in Myeloma” November 17, 2025 Community Workshops Facebook Live Replay: Dr. Joseph Mikhael Answers CAR T, MRD Negativity & Myeloma September 8, 2025 Facebook Live "33% of Late Relapse Myeloma Patients Disease-Free at 5 Years?” | ASCO & EHA Breakthroughs 2025 August 14, 2025 ASCO/EHA Early Relapsed Multiple Myeloma: What’s Changing in 2025 | Research Breakthroughs from ASCO & EHA August 7, 2025 Emerging Therapies Load More
